Src family kinases differentially influence glioma growth and motility

Molecular Oncology

Volumn 9, Issue 9, 2015, Pages 1783-1798

  Lewis Tuffin, Laura J ^a   Feathers, Ryan ^a   Hari, Priya ^a,d   Durand, Nisha ^a   Li, Zhimin ^a   Rodriguez, Fausto J ^b   Bakken, Katie ^c   Carlson, Brett ^c   Schroeder, Mark ^c   Sarkaria, Jann N ^c   Anastasiadis, Panos Z ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Dasatinib; Glioblastoma; Lyn kinase; Migration; Proliferation; Src family kinase

Indexed keywords

CASPASE 3; DASATINIB; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN KINASE SRC; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL DEATH; CELL LYSATE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE SILENCING; GLIOMA; IMMUNOHISTOCHEMISTRY; MOUSE; MTT ASSAY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TISSUE SECTION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BRAIN; BRAIN NEOPLASMS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DASATINIB; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MICE, NUDE; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 84940857288     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.06.001     Document Type: Article

References (50)

1. Achen M.G., Clauss M., Schnurch H., Risau W. The non-receptor tyrosine kinase Lyn is localised in the developing murine blood-brain barrier. Differentiation 1995, 59:15-24.
2. Ahluwalia M.S., de Groot J., Liu W.M., Gladson C.L. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 2010, 298:139-149.
3. Angers-Loustau A., Hering R., Werbowetski T.E., Kaplan D.R., Del Maestro R.F. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol. Cancer Res. 2004, 2:595-605.
4. Carlson B.L., Pokorny J.L., Schroeder M.A., Sarkaria J.N. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr. Protoc. Pharmacol. 2011, (Chapter 14), Unit 14.16, p. 14.16.1-14.16.23.
5. Colognato H., Ramachandrappa S., Olsen I.M., ffrench-Constant C. Integrins direct Src family kinases to regulate distinct phases of oligodendrocyte development. J. Cell Biol 2004, 167:365-375.
6. de Groot J., Milano V. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J. Neurooncol 2009, 95:151-163.
7. Ding Q., Stewart J., Olman M.A., Klobe M.R., Gladson C.L. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J. Biol. Chem. 2003, 278:39882-39891.
8. Du J., Bernasconi P., Clauser K.R., Mani D.R., Finn S.P., Beroukhim R., Burns M., Julian B., Peng X.P., Hieronymus H., Maglathlin R.L., Lewis T.A., Liau L.M., Nghiemphu P., Mellinghoff I.K., Louis D.N., Loda M., Carr S.A., Kung A.L., Golub T.R. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 2009, 27:77-83.
9. Feng H., Hu B., Liu K.W., Li Y., Lu X., Cheng T., Yiin J.J., Lu S., Keezer S., Fenton T., Furnari F.B., Hamilton R.L., Vuori K., Sarkaria J.N., Nagane M., Nishikawa R., Cavenee W.K., Cheng S.Y. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalpha-stimulated glioma tumorigenesis in mice and humans. J. Clin. Invest 2011, 121:4670-4684.
10. Frame M.C. Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci 2004, 117:989-998.
11. Garrett T.A., Van Buul J.D., Burridge K. VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Exp. Cell Res 2007, 313:3285-3297.
12. Giannini C., Sarkaria J.N., Saito A., Uhm J.H., Galanis E., Carlson B.L., Schroeder M.A., James C.D. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005, 7:164-176.
13. Goldenberg-Furmanov M., Stein I., Pikarsky E., Rubin H., Kasem S., Wygoda M., Weinstein I., Reuveni H., Ben-Sasson S.A. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 2004, 64:1058-1066.
14. Guarino M. Src signaling in cancer invasion. J. Cell Physiol 2010, 223:14-26.
15. Han N.M., Curley S.A., Gallick G.E. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 1996, 2:1397-1404.
16. Han X., Zhang W., Yang X., Wheeler C.G., Langford C.P., Wu L., Filippova N., Friedman G.K., Ding Q., Fathallah-Shaykh H.M., Gillespie G.Y., Nabors L.B. The role of Src family kinases in growth and migration of glioma stem cells. Int. J. Oncol. 2014, 45:302-310.
17. Huveldt D., Lewis-Tuffin L.J., Carlson B.L., Schroeder M.A., Rodriguez F., Giannini C., Galanis E., Sarkaria J.N., Anastasiadis P.Z. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One 2013, 8:e56505.
18. Iankov I.D., Msaouel P., Allen C., Federspiel M.J., Bulur P.A., Dietz A.B., Gastineau D., Ikeda Y., Ingle J.N., Russell S.J., Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res. Treat 2010, 122:745-754.
19. Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., Yokota A., Kamitsuji Y., Kawata E., Ashihara E., Nakaya Y., Naruoka H., Wakayama T., Nasu K., Asaki T., Niwa T., Hirabayashi K., Maekawa T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948-3954.
20. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., Thiemann M., Mueller W., Sykora J., Kuhn A., Schreglmann N., Letellier E., Zuliani C., Klussmann S., Teodorczyk M., Grone H.J., Ganten T.M., Sultmann H., Tuttenberg J., von Deimling A., Regnier-Vigouroux A., Herold-Mende C., Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
21. Lewis-Tuffin L.J., Rodriguez F., Giannini C., Scheithauer B., Necela B.M., Sarkaria J.N., Anastasiadis P.Z. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 2010, 5:e13665.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
23. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. WHO Classification of Tumours of the Central Nervous System 2007, IARC, Lyon. fourth ed.
24. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system.[erratum appears in Acta Neuropathol. 2007 Nov;114(5):547]. Acta Neuropathol. 2007, 114:97-109.
25. Lu K.V., Zhu S., Cvrljevic A., Huang T.T., Sarkaria S., Ahkavan D., Dang J., Dinca E.B., Plaisier S.B., Oderberg I., Lee Y., Chen Z., Caldwell J.S., Xie Y., Loo J.A., Seligson D., Chakravari A., Lee F.Y., Weinmann R., Cloughesy T.F., Nelson S.F., Bergers G., Graeber T., Furnari F.B., James C.D., Cavenee W.K., Johns T.G., Mischel P.S. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009, 69:6889-6898.
26. Lund C.V., Nguyen M.T., Owens G.C., Pakchoian A.J., Shaterian A., Kruse C.A., Eliceiri B.P. Reduced glioma infiltration in Src-deficient mice. J. Neurooncol 2006, 78:19-29.
27. Mariner D.J., Anastasiadis P., Keilhack H., Bohmer F.D., Wang J., Reynolds A.B. Identification of Src phosphorylation sites in the catenin p120ctn. J. Biol. Chem. 2001, 276:28006-28013.
28. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol 2006, 18:516-523.
29. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375:577-581.
30. Omri B., Crisanti P., Marty M.C., Alliot F., Fagard R., Molina T., Pessac B. The Lck tyrosine kinase is expressed in brain neurons. J. Neurochem. 1996, 67:1360-1364.
31. Park C.M., Park M.J., Kwak H.J., Lee H.C., Kim M.S., Lee S.H., Park I.C., Rhee C.H., Hong S.I. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 2006, 66:8511-8519.
32. Park S.I., Zhang J., Phillips K.A., Araujo J.C., Najjar A.M., Volgin A.Y., Gelovani J.G., Kim S.J., Wang Z., Gallick G.E. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008, 68:3323-3333.
33. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
34. Patel P.R., Sun H., Li S.Q., Shen M., Khan J., Thomas C.J., Davis M.I. Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorg. Med. Chem. Lett. 2013, 23:4398-4403.
35. Roof R.W., Haskell M.D., Dukes B.D., Sherman N., Kinter M., Parsons S.J. Phosphotyrosine (p-Tyr)-dependent and -independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of complex formation. Mol. Cell Biol 1998, 18:7052-7063.
36. Saporito M.S., Ochman A.R., Lipinski C.A., Handler J.A., Reaume A.G. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J. Pharmacol. Exp. Ther. 2012, 342:15-22.
37. Sarkaria J.N., Carlson B.L., Schroeder M.A., Grogan P., Brown P.D., Giannini C., Ballman K.V., Kitange G.J., Guha A., Pandita A., James C.D. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 2006, 12:2264-2271.
38. Sarkaria J.N., Yang L., Grogan P.T., Kitange G.J., Carlson B.L., Schroeder M.A., Galanis E., Giannini C., Wu W., Dinca E.B., James C.D. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 2007, 6:1167-1174.
39. Stettner M.R., Wang W., Nabors L.B., Bharara S., Flynn D.C., Grammer J.R., Gillespie G.Y., Gladson C.L. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. 2005, 65:5535-5543.
40. Summy J.M., Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22:337-358.
41. Summy J.M., Gallick G.E. Treatment for advanced tumors: SRC reclaims center stage. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2006, 12:1398-1401.
42. Theurillat J.P., Hainfellner J., Maddalena A., Weissenberger J., Aguzzi A. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am. J. Pathol. 1999, 154:581-590.
43. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev Biol 1997, 13:513-609.
44. Umemori H., Ogura H., Tozawa N., Mikoshiba K., Nishizumi H., Yamamoto T. Impairment of N-methyl-D-aspartate receptor-controlled motor activity in LYN-deficient mice. Neuroscience 2003, 118:709-713.
45. Umemori H., Wanaka A., Kato H., Takeuchi M., Tohyama M., Yamamoto T. Specific expressions of Fyn and Lyn, lymphocyte antigen receptor-associated tyrosine kinases, in the central nervous system. Brain Res. Mol. Brain Res. 1992, 16:303-310.
46. Werdich X.Q., Penn J.S. Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events. Angiogenesis 2005, 8:315-326.
47. Wick W., Weller M., Weiler M., Batchelor T., Yung A.W., Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011, 13:566-579.
48. Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22:9-18.
49. Yang L., Clarke M.J., Carlson B.L., Mladek A.C., Schroeder M.A., Decker P., Wu W., Kitange G.J., Grogan P.T., Goble J.M., Uhm J., Galanis E., Giannini C., Lane H.A., James C.D., Sarkaria J.N. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin. Cancer Res. 2008, 14:3993-4001.
50. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.